CN114869795A - Preparation method of whitening composition for improving solubility of active components, product and application thereof - Google Patents
Preparation method of whitening composition for improving solubility of active components, product and application thereof Download PDFInfo
- Publication number
- CN114869795A CN114869795A CN202210322071.8A CN202210322071A CN114869795A CN 114869795 A CN114869795 A CN 114869795A CN 202210322071 A CN202210322071 A CN 202210322071A CN 114869795 A CN114869795 A CN 114869795A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- whitening
- lecithin
- solubility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000002087 whitening effect Effects 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims abstract description 64
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 55
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 36
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 36
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 36
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 36
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 36
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 27
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 27
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 27
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 27
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 27
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 27
- 229940025878 hesperidin Drugs 0.000 claims abstract description 27
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 23
- 239000000787 lecithin Substances 0.000 claims abstract description 23
- 229940067606 lecithin Drugs 0.000 claims abstract description 23
- 235000010445 lecithin Nutrition 0.000 claims abstract description 23
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract description 22
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 claims abstract description 20
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 claims abstract description 20
- 238000010438 heat treatment Methods 0.000 claims abstract description 20
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 238000004945 emulsification Methods 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 238000010992 reflux Methods 0.000 claims abstract description 10
- UJEADPSEBDCWPS-SGJODSJKSA-N (2R,3R)-1-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]butane-1,2,3,4-tetrol Chemical class C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C([C@H](O)[C@H](O)CO)O UJEADPSEBDCWPS-SGJODSJKSA-N 0.000 claims abstract description 6
- 239000008236 heating water Substances 0.000 claims abstract description 3
- 239000007908 nanoemulsion Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 14
- -1 mannosylerythritol ester Chemical class 0.000 claims description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 12
- 229940083466 soybean lecithin Drugs 0.000 claims description 12
- 239000003674 animal food additive Substances 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 description 37
- 229960002255 azelaic acid Drugs 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 235000011187 glycerol Nutrition 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 229940113120 dipropylene glycol Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910001566 austenite Inorganic materials 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method of a whitening composition for improving the solubility of active components, a product and application thereof, wherein azelaic acid, ferulic acid, dipropylene glycol and glycerol are mixed and heated to obtain a composition 1; mixing and heating glyceryl acetate, hesperidin and aescin to obtain composition 2; slowly adding the composition 1 into the composition 2, and stirring while adding to obtain a composition 3; mixing and heating water, mannosylerythritol lipids, dipalmitoylphosphatidylcholine and lecithin, and homogenizing until the lecithin is completely dissolved to obtain a composition 4; adding the composition 3 into the composition 4, and homogenizing and stirring until complete emulsification; and (3) adding the product obtained in the step (5) into a high-pressure homogenizer, and refluxing under high pressure.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a preparation method of a whitening composition for improving the solubility of an active component, a product and application thereof.
Background
At present, whitening raw materials and whitening cosmetics on the market are more and more, many consumers have symptoms of unobvious effect or sensitive skin and the like after using whitening products, and safe and effective whitening still is a problem to be solved urgently.
Ferulic acid is derived from Chinese herbal medicines such as angelica sinensis and the like, is a very safe and effective whitening component, can inhibit the activity of melanocyte B16V and tyrosinase, and has the effects of scavenging oxygen free radicals and good antioxidation. Besides, ferulic acid also has the function of absorbing ultraviolet rays and preventing sunburn. Azelaic acid can competitively inhibit the activity of tyrosinase, and has the effects of directly inhibiting and accelerating keratinocyte metabolism for melanocyte with hyperfunction of structural disorder or proliferation, thereby improving skin pigmentation. Hesperidin can regulate the phosphorylation levels of PI3K and Akt down, and can influence the expression of the most important transcription factor MITF in the melanin synthesis process and finally influence the melanin synthesis. Aescin has good anti-inflammatory effect, and can prevent melanin deposition caused by inflammation, and relieve irritation and erythema caused by whitening agent.
However, although the natural sources of ferulic acid, azelaic acid, hesperidin and aescin have good efficacy, the natural sources are not soluble in water and oil, the use is limited, the emulsion is broken due to precipitation even if the natural sources are made into cream, the product is extremely unstable, and the ferulic acid is easy to oxidize to influence the effect of the ferulic acid.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
As one aspect of the present invention, the present invention provides a method for preparing a whitening composition for improving the solubility of an active ingredient, which comprises the steps of,
step 1: mixing azelaic acid, ferulic acid, dipropylene glycol and glycerol and heating to provide composition 1;
step 2: mixing and heating glyceryl acetate, hesperidin and aescin to obtain composition 2;
and step 3: slowly adding the composition 1 into the composition 2, and stirring while adding to obtain a composition 3;
and 4, step 4: mixing and heating water, mannosylerythritol lipids, dipalmitoylphosphatidylcholine and lecithin, and homogenizing until the lecithin is completely dissolved to obtain a composition 4;
and 5: adding the composition 3 into the composition 4, and homogenizing and stirring until complete emulsification;
step 6: adding the product obtained in the step (5) into a high-pressure homogenizer, and performing high-pressure reflux for 8-9 times under the pressure of 800-900 bar to obtain the whitening nano emulsion;
the feed additive comprises, by mass, 5-32 parts of azelaic acid, 1-14 parts of ferulic acid, 0.5-5 parts of hesperidin, 1-2 parts of aescin, 1-5 parts of dipalmitoyl phosphatidylcholine, 1-4 parts of soybean lecithin, 0.1-1 part of mannosylerythritol ester, 4-6 parts of glycerol acetate, 5-12 parts of glycerol, 1-7 parts of dipropylene glycol and the balance of water to 100 parts.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: in the step 1, heating is carried out until the temperature is 60-70 ℃.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: in the step 2, heating is carried out until the temperature is 60-70 ℃.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: in the step 5, heating is carried out until the temperature is 60 ℃.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: in step 6, the pressure is 850 bar.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: in step 5, the homogenizing time is 3-5 min, and the rotating speed is 10000-15000 r/s.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: the lecithin is soybean lecithin, and the phosphatidylcholine content of the lecithin is 40%.
As a preferred embodiment of the method for preparing the whitening composition for improving the solubility of the active ingredient according to the present invention: the feed additive comprises, by mass, 27-30 parts of azelaic acid, 13-14 parts of ferulic acid, 3-5 parts of hesperidin, 1-2 parts of aescin, 4-5 parts of dipalmitoylphosphatidylcholine, 2-3 parts of lecithin, 0.5-1 part of mannosylerythritol ester, 4-5 parts of glycerol acetate, 10-12 parts of glycerol, 6-7 parts of dipropylene glycol and the balance of water to 100 parts.
As another aspect of the invention, the invention provides an application of the whitening composition in preparing whitening masks, essences, emulsions and creams.
The invention has the beneficial effects that: according to the invention, a nano-emulsification technology is adopted, a proper solvent, an emulsifier and the like are searched for to completely dissolve functional raw materials, and the nano-emulsion with uniform particle size is prepared, so that the nano-emulsion can be added into an aqueous product and an emulsified body, and meanwhile, the slow release permeation of the nano-emulsion in skin is increased by adopting hydrogenated phosphatidylcholine, lecithin (PC40) and mannitol erythritol lipid obtained by biological fermentation, and the effects of mildness, safety and high efficiency whitening are achieved. The compound of the dipalmitoyl phosphatidylcholine and the soybean lecithin (PC40) emulsifier not only improves the emulsification effect, but also can assist in solubilizing azelaic acid, ferulic acid and hesperidin, so that the emulsion is stable and does not break emulsion while the solubility of the azelaic acid, the ferulic acid and the hesperidin is improved.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
FIG. 1 is a graph showing the particle size distribution of the product of example 1.
Fig. 2 is a transdermal fluorescence image of the whitening nanoemulsion of the control group and the embodiment 1 of the invention.
FIG. 3 is a graph of MI values tested in example 1.
FIG. 4 is the melanin reduction rate over 3 weeks tested in example 1.
FIG. 5 is the ITA ° test value within 21 days of the test of example 1.
FIG. 6 is the gloss enhancement rate over 3 weeks tested in example 1.
Fig. 7 is a skin penetration test chart of the whitening combination emulsion of the control example 1.
Fig. 8 is MI values measured within 21 days of the whitening combination emulsion of comparative example 1.
Fig. 9 is a melanin reduction rate of the whitening combination emulsion of comparative example 1 for 3 weeks.
Fig. 10 is an ITA ° measured within 21 days of the whitening combination emulsion of comparative example 1.
Fig. 11 is a graph showing the brightness improvement rate of the whitening combination emulsion of comparative example 1 in 3 weeks.
FIG. 12 is a graph showing the particle size distribution of the product of comparative example 1.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with examples are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Furthermore, the references herein to "one embodiment" or "an embodiment" refer to a particular feature, structure, or characteristic that may be included in at least one implementation of the present invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
The whitening nano-emulsion disclosed by the invention comprises the following raw materials in parts by weight: 5-30 parts of azelaic acid, 1-14 parts of ferulic acid, 0.5-5 parts of hesperidin, 1-2 parts of aescin, 1-5 parts of dipalmitoylphosphatidylcholine, 1-4 parts of soybean lecithin (PC40), 0.1-1 part of mannosylerythritol ester, 4-6 parts of glycerol acetate, 5-12 parts of glycerol and dipropylene glycol (C) 6 H 14 O 3 )1-7 parts of water to 100 parts.
The preparation method of the whitening composition comprises the following steps:
1. mixing azelaic acid, ferulic acid, dipropylene glycol and glycerol, and heating to 60-70 deg.C for complete dissolution to obtain composition 1;
2. mixing glyceryl acetate, hesperidin and aescin, and heating to 60-70 deg.C for completely dissolving to obtain composition 2;
3. slowly adding composition 1 into composition 2 at 60-70 deg.C under stirring to obtain composition 3;
4. mixing water, mannosylerythritol lipid, dipalmitoylphosphatidylcholine and lecithin, heating to 60 deg.C, and homogenizing until lecithin is completely dissolved to obtain composition 4;
5. adding the composition 3 into the composition 4, homogenizing at 10000-15000 r/s for 3-5 minutes until complete emulsification;
6. and adding the emulsified emulsion into a high-pressure homogenizer, and performing high-pressure reflux for 8-9 times under the pressure of 850bar to obtain the whitening nano emulsion.
Example 1:
the whitening nano-emulsion disclosed by the invention comprises the following raw materials in parts by weight: 31 parts of azelaic acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 5 parts of dipalmitoyl phosphatidylcholine, 3 parts of lecithin (PC40), 1 part of mannosylerythritol ester, 5 parts of glycerol acetate, 12 parts of glycerol, and dipropylene glycol (C) 6 H 14 O 3 )7 parts of water to 100 parts.
1. Mixing azelaic acid, ferulic acid, dipropylene glycol and glycerol, and heating to 65 deg.C for complete dissolution to obtain composition 1;
2. mixing glyceryl acetate, hesperidin and aescin, and heating to 65 deg.C to completely dissolve to obtain composition 2;
3. slowly adding composition 1 to composition 2 while maintaining at 65 deg.C, and stirring to obtain composition 3;
4. mixing water, mannosylerythritol lipids, dipalmitoylphosphatidylcholine and lecithin, heating to 60 deg.C, and homogenizing until the lecithin is completely dissolved to obtain composition 4;
5. adding the composition 3 into the composition 4, and homogenizing and stirring for 4 minutes until complete emulsification;
6. and adding the emulsified emulsion into a high-pressure homogenizer, and performing high-pressure reflux for 8 times under the pressure of 850bar to obtain the whitening nano emulsion.
The experimental results are as follows: the obtained nano-emulsion is transparent viscous liquid, and the particle size of the nano-emulsion is measured by adopting a Zeta potential and nano-particle size analyzer; and placing the mixture in a high-low temperature circulating (-15 ℃ -48 ℃) thermostat to determine the high-low temperature stability of the mixture. Fig. 1 is a particle size distribution diagram measured by a Zeta potential and nano-particle size analyzer, and it can be seen that the nanoemulsion has a more concentrated particle size distribution and a better dispersity. From the figure, it can be seen that the average particle size of the nanoemulsion ranges from 40 to 50 nm.
The stability test results are as follows: the cycle did not change significantly one month.
Transdermal experiment: the skin penetration depth of the whitening nanoemulsion added with a fat-soluble fluorescent agent, namely nile red (the mass fraction of 0.0001 percent) is observed by adopting a fluorescence microscope. The two samples were cut into strips after transdermal penetration and coated with SAKURA cryo-embedding medium. And after freezing for 24 hours, placing the pigskin on a freezing microtome for slicing, wherein the thickness is controlled to be 20-40 mu m. Setting the fluorescence type to the excitation wavelength: 488nm, emission wavelength: 571-741 nm, and observing the transdermal effect of the whitening nanoemulsion under the fluorescent condition. Fig. 2 is a transdermal fluorescence image of a control group and the whitening nanoemulsion of the invention. Fig. 2 shows that a-1 is a transdermal experimental white light channel diagram of a control group whitening emulsion, a-2 is a transdermal experimental fluorescence diagram of the control group whitening emulsion, b-1 is a transdermal experimental white light channel diagram of the whitening nanoemulsion of the present invention, and b-2 is a transdermal experimental fluorescence diagram of the whitening nanoemulsion of the present invention, so that the whitening nanoemulsion of the present invention has good transdermal properties. Spot-pasting experiment: the spot test method comprises the following steps: selecting qualified spot test equipment, placing 0.020-0.025 mL (0.020-0.025 g) of a test object in a spot tester by a closed spot test method, externally applying a hypoallergenic adhesive tape to the curved side of the forearm of the test object, removing the test object after 24 hours, removing the spot tester of the test object for 30min, and observing skin reaction after the indentation disappears. If the result is negative, the test is observed once more at 24h and 48h after the patch test. The results were recorded according to the skin adverse reaction grading criteria (table below).
TABLE 1 skin closed Patch test skin response grading Standard
Through detection, 30 people do not have adverse skin reactions in 30 closed skin patch tests, which are detailed in table 2.
TABLE 2 cosmetic body Patch test results
Evaluation experiment of human whitening efficacy: the skin melanin content (MI value) was measured using the german CK skin tester Mexameter MX18 probe, and higher measured values indicate higher melanin content in the skin. Skin brightness (dark yellowness) was measured with a Colormeter probe (ITA ° value), the ITA ° value being the individual type angle of the skin, the greater the ITA ° value, the brighter the skin, and vice versa the darker the skin. After the test subject cleans the face every day, the whitening nano-emulsion is added at 1.25 mu L/cm 2 The test part was coated with uniform coating density 1 time each day in the morning and evening for 21 days. FIG. 3 shows MI values measured in 21 days, and FIG. 4 shows melanin reduction rate in 3 weeks. As can be seen from the figure, the whitening nanoemulsion can well reduce the melanin content of the skin and improve the brightness. Fig. 5 is the ITA ° test value in 21 days, and fig. 6 is the gloss improvement rate in 3 weeks.
The combination of the glycerol and the dipropylene glycol ensures that the oil-water distribution coefficient is just proper, and the emulsion is stable and does not break. Meanwhile, the two emulsifiers, namely dipalmitoyl phosphatidylcholine and soybean lecithin, are compounded, so that the emulsifying effect is improved, and the solubilization of azelaic acid, ferulic acid and hesperidin can be assisted, so that the emulsion is stable and does not break emulsion while the solubility of azelaic acid, ferulic acid and hesperidin is improved. The invention adopts the soybean lecithin with 40 wt% of phosphatidylcholine content to be compounded with dipalmitoyl phosphatidylcholine, probably because the mixture of phosphoric acid, choline, fatty acid, glycolipid, triglyceride and the like in the soybean lecithin can promote the dissolution of azelaic acid and ferulic acid after being compounded with other components, and the compounding of the two emulsifiers improves the stability of the emulsion.
Comparative example 1:
the whitening nano-emulsion disclosed by the invention comprises the following raw materials in parts by weight: 31 parts of azelaic acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 5 parts of dipalmitoyl phosphatidylcholine, 3 parts of lecithin (PC40), 1 part of mannosylerythritol ester, 5 parts of glycerol acetate, 12 parts of glycerol, and dipropylene glycol (C) 6 H 14 O 3 )7 parts of water to 100 parts.
The preparation method comprises the following steps:
1. mixing azelaic acid, ferulic acid, dipropylene glycol and glycerol, and heating to 65 deg.C for complete dissolution to obtain composition 1;
2. mixing glyceryl acetate, hesperidin and aescin, and heating to 65 deg.C for completely dissolving to obtain composition 2;
3. slowly adding composition 1 to composition 2 while maintaining at 65 deg.C, and stirring to obtain composition 3;
4. mixing water, mannosylerythritol lipids, dipalmitoylphosphatidylcholine and lecithin, heating to 60 deg.C, and homogenizing until the lecithin is completely dissolved to obtain composition 4;
5. adding the composition 3 into the composition 4, homogenizing and stirring for 3-5 minutes until complete emulsification;
6. and adding the emulsified emulsion into a high-pressure homogenizer, and performing high-pressure reflux for 3 times under the pressure of 400bar to obtain the whitening nano emulsion.
The experimental results are as follows: the appearance is opaque emulsion, the particle size is about 100-120nm, and the graph is shown in figure 12.
The stability test results are as follows: the sample is placed in a high-low temperature constant temperature box for circulation experiment, and no obvious change is caused within 1 month.
Fig. 7 is a graph of a transdermal experiment of the whitening combined emulsion of the embodiment, c-1 is a graph of a transdermal experiment white light channel of the whitening nanoemulsion of the embodiment, and c-2 is a graph of a transdermal experiment fluorescence of the whitening nanoemulsion of the embodiment. Fig. 8 shows MI values measured within 21 days of the whitening combination emulsion. Fig. 9 is the melanin reduction rate of the whitening combination emulsion for 3 weeks. Fig. 10 is the ITA ° measured over 21 days for the whitening combination emulsion. Fig. 11 shows the brightness improvement rate of the whitening combination emulsion within 3 weeks.
The factors that cause emulsion instability are mainly the following: layering, flocculation, phase inversion, polymerization, and austenite ripening. The austenite curing means that small particles in a system gradually become smaller and are attached to large particles, and finally the phenomenon that the small particles are smaller and the large particles are larger is caused, and the pressure and the reflux frequency for preparing the nano emulsion influence the particle size distribution, the transdermal effect and the whitening effect of a product. The nano emulsion prepared by the method has larger and uneven grain diameter and can cause austenite curing because the force for breaking the emulsion is smaller with smaller pressure and reflux times; the excessive reflux times caused by excessive pressure can cause re-agglomeration of the nano emulsion after excessive scattering; the large particle size causes the active substance not to easily permeate into the skin, thereby affecting the whitening effect, so that it is very important to obtain a stable product having excellent skin penetration and whitening effects by optimizing a proper pressure and adjusting an optimal number of times of reflux.
Comparative example 2:
31 parts of azelaic acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 5 parts of dipalmitoyl phosphatidylcholine, 3 parts of lecithin (PC40), 1 part of mannosylerythritol ester, 5 parts of glycerol acetate, 12 parts of butanediol and propylene glycol (C) 3 H 8 O 2 )7 parts of water to 100 parts.
The preparation method is the same as that of example 1.
The experimental results are as follows: it was found that if glycerin and dipropylene glycol were replaced with butylene glycol and propylene glycol (C) 3 H 8 O 2 ) Can cause that azelaic acid and ferulic acid can not be completely dissolved, crystal is separated out after cooling, and emulsion is broken by emulsion.
The solubility of azelaic acid and ferulic acid is between that of water and oil, and it is difficult to find suitable solvents, which are neither soluble in oil nor soluble in water, and glycerin or propylene glycol alone, although high temperature can dissolve it, will precipitate out of the system when the temperature is reduced to room temperature, and the product will eventually be unstable. While it is more difficult to dissolve azelaic acid and ferulic acid simultaneously and to find a solvent that is compatible with them simultaneously, this technical problem is not solved in the prior art.
Comparative example 3:
31 parts of azelaic acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 805 parts of tween, 3 parts of caprylic/capric triglyceride, 1 part of mannosylerythritol ester, 5 parts of glycerol acetate, 12 parts of glycerol and dipropylene glycol (C) 6 H 14 O 3 )7 parts of water to 100 parts.
The preparation method is the same as that of example 1.
The experimental results are as follows: the emulsion is demulsified after being cooled, the emulsification effect is not good, and the experimental requirements can not be met.
Comparative example 4:
the combination of the whitening nano-emulsion of the invention is nonane II31 parts of acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 8 parts of dipalmitoyl phosphatidylcholine, 1 part of mannosylerythritol, 5 parts of glycerol acetate, 12 parts of glycerol and dipropylene glycol (C) 6 H 14 O 3 )7 parts of water to 100 parts.
The preparation method is the same as that of example 1.
The experimental results are as follows: more precipitate is separated out after the emulsion is cooled. The compound of the dipalmitoyl phosphatidylcholine and the soybean lecithin (PC40) emulsifier not only improves the emulsification effect, but also can assist in solubilizing azelaic acid, ferulic acid and hesperidin, so that the emulsion is stable and does not break emulsion while the solubility of the azelaic acid, the ferulic acid and the hesperidin is improved. And the effect is poor when dipalmitoyl phosphatidylcholine is used alone, the solubility of azelaic acid, ferulic acid and hesperidin is obviously reduced, and the requirements of emulsification and solubilization can not be met.
Comparative example 5:
the whitening nano-emulsion disclosed by the invention comprises the following raw materials in parts by weight: 31 parts of azelaic acid, 14 parts of ferulic acid, 5 parts of hesperidin, 2 parts of aescin, 5 parts of dipalmitoyl phosphatidylcholine, 3 parts of lecithin (PC80), 1 part of mannosylerythritol ester, 5 parts of glycerol acetate, 12 parts of glycerol, and dipropylene glycol (C) 6 H 14 O 3 )7 parts of water to 100 parts.
The preparation method is the same as that of example 1.
The experimental results are as follows: the emulsion is cooled and precipitates. The invention discovers that the poor solubility of azelaic acid and ferulic acid, the precipitation of the emulsion and the instability of the emulsion are caused after the soybean lecithin with 80 wt% of phosphatidylcholine content and dipalmitoyl phosphatidylcholine are compounded.
In summary, the invention adopts the nano-emulsification technology, finds the proper solvent, emulsifier and the like to completely dissolve the functional raw materials and prepare the nano-emulsion with uniform particle size, can simultaneously dissolve 32% azelaic acid, 14% ferulic acid, 5% hesperidin and 2% aescin, ensures that the emulsion is very stable and does not break emulsion, has no precipitation and is directly mixed and dissolved, does not need to introduce ethanol and blow-dry and other complicated steps in the dissolving process, the solvent and the emulsifier are the functional components for whitening and moisturizing, and can be used as the solvent to dissolve the active components of azelaic acid, ferulic acid and the like while realizing emulsification and moisturizing, thereby simplifying the process and being safer, the composition of the invention can be added into water aqua products or emulsified bodies, and simultaneously adopts hydrogenated phosphatidylcholine, soybean lecithin (PC40) and mannose erythritol ester obtained by biological fermentation to increase the slow-release permeation of the composition in skin, the effects of mildness, safety and high-efficiency whitening are achieved.
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Claims (9)
1. A preparation method of a whitening composition for improving the solubility of an active component is characterized by comprising the following steps: the method comprises the following steps of (1),
step 1: mixing azelaic acid, ferulic acid, dipropylene glycol and glycerol and heating to obtain composition 1;
step 2: mixing and heating glyceryl acetate, hesperidin and aescin to obtain composition 2;
and step 3: slowly adding the composition 1 into the composition 2, and stirring while adding to obtain a composition 3;
and 4, step 4: mixing and heating water, mannosylerythritol lipids, dipalmitoylphosphatidylcholine and lecithin, and homogenizing until the lecithin is completely dissolved to obtain a composition 4;
and 5: adding the composition 3 into the composition 4, and homogenizing and stirring until complete emulsification;
step 6: adding the product obtained in the step (5) into a high-pressure homogenizer, and performing high-pressure reflux for 8-9 times under the pressure of 800-900 bar to obtain the whitening nano emulsion;
the feed additive comprises, by mass, 5-32 parts of azelaic acid, 1-14 parts of ferulic acid, 0.5-5 parts of hesperidin, 1-2 parts of aescin, 1-5 parts of dipalmitoyl phosphatidylcholine, 1-4 parts of soybean lecithin, 0.1-1 part of mannosylerythritol ester, 4-6 parts of glycerol acetate, 5-12 parts of glycerol, 1-7 parts of dipropylene glycol and the balance of water to 100 parts.
2. The method for preparing a whitening composition according to claim 1, characterized in that: in the step 1, heating is carried out until the temperature is 60-70 ℃.
3. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: in the step 2, heating is carried out until the temperature is 60-70 ℃.
4. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: in the step 5, heating is carried out until the temperature is 60 ℃.
5. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: in step 6, the pressure is 850 bar.
6. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: in step 5, the homogenizing time is 3-5 min, and the rotating speed is 10000-15000 r/s.
7. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: the lecithin is soybean lecithin, and the phosphatidylcholine content of the lecithin is 40%.
8. The method for preparing a whitening composition for improving the solubility of active ingredients according to claim 1 or 2, characterized in that: the feed additive comprises, by mass, 27-30 parts of azelaic acid, 13-14 parts of ferulic acid, 3-5 parts of hesperidin, 1-2 parts of aescin, 4-5 parts of dipalmitoylphosphatidylcholine, 2-3 parts of lecithin, 0.5-1 part of mannosylerythritol ester, 4-5 parts of glycerol acetate, 10-12 parts of glycerol, 6-7 parts of dipropylene glycol and the balance of water to 100 parts.
9. Use of the whitening composition of claim 1 in the preparation of whitening masks, essences, lotions and creams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210322071.8A CN114869795B (en) | 2022-03-29 | 2022-03-29 | Preparation method of whitening composition, product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210322071.8A CN114869795B (en) | 2022-03-29 | 2022-03-29 | Preparation method of whitening composition, product and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114869795A true CN114869795A (en) | 2022-08-09 |
| CN114869795B CN114869795B (en) | 2024-01-26 |
Family
ID=82670148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210322071.8A Active CN114869795B (en) | 2022-03-29 | 2022-03-29 | Preparation method of whitening composition, product and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114869795B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117567270A (en) * | 2023-11-20 | 2024-02-20 | 江南大学 | Alcohol amine-azelaic acid supermolecule ionic salt and preparation and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925679A (en) * | 1995-06-06 | 1999-07-20 | Neutrogena Corporation | Topical vehicles containing solubilized and stabilized azelaic acid |
| KR20100057274A (en) * | 2008-11-21 | 2010-05-31 | (주)아모레퍼시픽 | Cosmetic composition for skin whitening |
| CN104490628A (en) * | 2014-12-01 | 2015-04-08 | 唯美度科技（北京）有限公司 | Natural skin-whitening nourishing after-bath lotion and preparation method thereof |
| CN105581919A (en) * | 2015-11-26 | 2016-05-18 | 北京工商大学 | Ferulic acid and phospholipid complex and application thereof to preparation of skin-whitening cosmetics |
| CN109481319A (en) * | 2018-11-22 | 2019-03-19 | 杭州千岛湖天鑫有限公司 | A kind of micro-nano lotion of camellia oil and preparation method thereof |
| CN110946796A (en) * | 2019-12-23 | 2020-04-03 | 苏州绿叶日用品有限公司 | Whitening composition containing endothelin antagonist and preparation method and application thereof |
| CN111956637A (en) * | 2020-09-02 | 2020-11-20 | 谢志辉生物医药研究院(广州)有限公司 | Acne-removing ointment and preparation method thereof |
-
2022
- 2022-03-29 CN CN202210322071.8A patent/CN114869795B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925679A (en) * | 1995-06-06 | 1999-07-20 | Neutrogena Corporation | Topical vehicles containing solubilized and stabilized azelaic acid |
| KR20100057274A (en) * | 2008-11-21 | 2010-05-31 | (주)아모레퍼시픽 | Cosmetic composition for skin whitening |
| CN104490628A (en) * | 2014-12-01 | 2015-04-08 | 唯美度科技（北京）有限公司 | Natural skin-whitening nourishing after-bath lotion and preparation method thereof |
| CN105581919A (en) * | 2015-11-26 | 2016-05-18 | 北京工商大学 | Ferulic acid and phospholipid complex and application thereof to preparation of skin-whitening cosmetics |
| CN109481319A (en) * | 2018-11-22 | 2019-03-19 | 杭州千岛湖天鑫有限公司 | A kind of micro-nano lotion of camellia oil and preparation method thereof |
| CN110946796A (en) * | 2019-12-23 | 2020-04-03 | 苏州绿叶日用品有限公司 | Whitening composition containing endothelin antagonist and preparation method and application thereof |
| CN111956637A (en) * | 2020-09-02 | 2020-11-20 | 谢志辉生物医药研究院(广州)有限公司 | Acne-removing ointment and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117567270A (en) * | 2023-11-20 | 2024-02-20 | 江南大学 | Alcohol amine-azelaic acid supermolecule ionic salt and preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114869795B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1353629B1 (en) | Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields | |
| EP1837056B1 (en) | Anti-aging composition containing phloretin | |
| CN108938439A (en) | Liquid crystal type emulsification composition and its preparation method and application | |
| CN108721161B (en) | Hair-nourishing composition and preparation method of liposome thereof | |
| CN107802512B (en) | Vitamin E nanoemulsion, nano cream and preparation method thereof | |
| CN110731923A (en) | Enhanced moisturizing cosmetic compositions | |
| CN111544317B (en) | Anti-aging composition cationic nano-liposome and preparation method and application thereof | |
| KR101455684B1 (en) | Emulsion type-cosmetic composition containing liquid crystal for improvement of skin barrier and skin regeneration effect | |
| CN107613945B (en) | Genistein methyl ether-containing nanoliposome, preparation method thereof and cosmetic composition comprising same | |
| CN114869795A (en) | Preparation method of whitening composition for improving solubility of active components, product and application thereof | |
| CN114042006B (en) | Centella asiatica ethosome and preparation method thereof | |
| KR101667765B1 (en) | Nano-particle composition of skin whitening with improved skin penetration rate | |
| KR101868481B1 (en) | Cosmetic composition for moisturizing skin with snowflake pattern and method of thereof | |
| CN113952253A (en) | Composition for improving stability of cosmetics, cosmetics containing composition and preparation method of cosmetics | |
| AU2018272337B2 (en) | Emulsified liposome composition and preparation method therefor | |
| JP2001114636A (en) | Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion | |
| FR3090335A1 (en) | Composition comprising a monoglyceride, a tartaric ester of monoglyceride and a derivative of salicylic acid | |
| FR3090360A1 (en) | Composition comprising a polysaccharide, a polyol and a specific ester | |
| Chaiyana et al. | The fatty acid compositions, irritation properties, and potential applications of teleogryllus mitratus oil in nanoemulsion development | |
| JPH10194982A (en) | Collagenase inhibitor and skin lotion for senescence prevention containing the same | |
| KR102470948B1 (en) | Preparation method of enhanced liquid-crystal emulsion | |
| CN115919705B (en) | Whitening composite microemulsion cosmetic intermediate and application thereof | |
| KR101787583B1 (en) | Cosmetic composition comprising maackia amurensis extract having effect of skin wrinkle improvement and cosmetic using the same | |
| JP4723064B2 (en) | Anti-aging agent and cosmetics containing the same | |
| Peranginangin et al. | Antioxidant Activity Test of the Red Yeast Rice Extract and the Formulation in a Cream Preparations Andit’S Penetration and Safety Test At Rabbit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |